-+ 0.00%
-+ 0.00%
-+ 0.00%
Rein Therapeutics Q3 net loss per share narrows 71% to $0.06
Share
Listen to the news
Rein Therapeutics Q3 net loss per share narrows 71% to $0.06
  • Rein Therapeutics’ third-quarter 2026 net loss narrowed to $5.54 million.
  • R&D expenses more than doubled year over year to $4.38 million, while G&A expenses fell 31% to $2.62 million.
  • Cash, cash equivalents and marketable securities totaled $36.5 million at September 30, expected to fund operations into the first quarter of 2028.
  • Blinded, pooled RENEW trial data showed lung-function improvement in 33% of evaluable patients at Week 12 but did not establish a treatment effect.
  • RENEW enrollment reached 75% in November, with topline results expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160730PRIMZONEFULLFEED9877927) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending